Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
暂无分享,去创建一个
S. Terry | S. Chouaib | J. Thiery | S. Buart | Amirtharaj Francis | Goutham Hassan Venkatesh | P. Bravo | Rania Faouzi Zaarour | Walid El-Sayed | Stéphanie Buart
[1] S. Liang,et al. Preclinical evidence of the enhanced effectiveness of combined rapamycin and AICAR in reducing kidney cancer , 2018, Molecular oncology.
[2] Weijun Peng,et al. Jianpi Jiedu decoction, a traditional Chinese medicine formula, inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1α/VEGF pathway. , 2018, Journal of ethnopharmacology.
[3] W. Liu,et al. Two-photon fluorescent probe for detection of nitroreductase and hypoxia-specific microenvironment of cancer stem cell. , 2018, Analytica Chimica Acta.
[4] Juan Ma,et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death‐ligand 1 expression by reducing hypoxia‐inducible factor‐1&agr; and STAT3 , 2018, Pharmacological research.
[5] H. Ling,et al. Signalling mechanism(s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[6] Ambrose J. Carr,et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.
[7] Enrique J. deAndrés-Galiana,et al. NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. , 2018, Cancer research.
[8] I. Petersen,et al. Stem cell transcription factor SOX2 in synovial sarcoma and other soft tissue tumors. , 2018, Pathology, research and practice.
[9] Qiang Yu,et al. Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer , 2018, Proceedings of the National Academy of Sciences.
[10] G. Semenza,et al. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment. , 2018, Cancer research.
[11] Jung-Hwan Yoon,et al. Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro. , 2018, Oncology letters.
[12] Jiaqi Tang,et al. Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression , 2018, Cancers.
[13] S. Chevillard,et al. Breast cancer stem cell-like cells generated during TGFβ-induced EMT are radioresistant , 2018, Oncotarget.
[14] S. Bhattacharyya,et al. Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells , 2018, Cancer Cell International.
[15] B. Vojtesek,et al. STAT3, stem cells, cancer stem cells and p63 , 2018, Cellular & Molecular Biology Letters.
[16] G. Kaur,et al. Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges , 2018, Current Treatment Options in Oncology.
[17] C. Zwieb,et al. A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers , 2018, Clinical Cancer Research.
[18] Inna Kuperstein,et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. , 2018, Cancer cell.
[19] T. S. Ramasamy,et al. Cancer stem cells as key drivers of tumour progression , 2018, Journal of Biomedical Science.
[20] M. de la Guardia,et al. Modulating tumor hypoxia by nanomedicine for effective cancer therapy , 2018, Journal of cellular physiology.
[21] B. Coyle,et al. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells , 2018, Cellular Oncology.
[22] Camille Stephan-Otto Attolini,et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.
[23] Yongping Song,et al. TGFβ1-induced down-regulation of microRNA-138 contributes to epithelial-mesenchymal transition in primary lung cancer cells. , 2018, Biochemical and biophysical research communications.
[24] C. Zahnow,et al. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells , 2018, Proceedings of the National Academy of Sciences.
[25] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[26] T. Gajewski,et al. Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.
[27] V. Keshamouni,et al. Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer , 2018, The Journal of clinical investigation.
[28] Jeffrey H. Chuang,et al. Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma , 2017, Oncotarget.
[29] W. Blalock,et al. MiRNA-210: A Current Overview. , 2017, Anticancer research.
[30] F. Nicolantonio,et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth , 2017, Nature.
[31] P. Davis,et al. Subcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: a review , 2017, Journal of Clinical Pathology.
[32] Tiara Bunga Mayang Permata,et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.
[33] S. Terry,et al. Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity , 2017, Front. Immunol..
[34] J. Bergh,et al. An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression , 2017, Cancer cell.
[35] Shawn M. Gillespie,et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.
[36] S. Terry,et al. Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3 , 2017, Oncotarget.
[37] M. Simon,et al. Oxygen availability and metabolic reprogramming in cancer , 2017, The Journal of Biological Chemistry.
[38] B. Groner,et al. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.
[39] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[40] B. Goh,et al. Do STAT3 inhibitors have potential in the future for cancer therapy? , 2017, Expert opinion on investigational drugs.
[41] F. Azuaje,et al. CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT , 2017, Oncoimmunology.
[42] J. Thiery,et al. New insights into the role of EMT in tumor immune escape , 2017, Molecular oncology.
[43] V. Gopalan,et al. The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer. , 2017, Clinical colorectal cancer.
[44] T. Cloughesy,et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma , 2017, Neuro-oncology.
[45] Q. Dong,et al. Clinical and prognostic significance of HIF-1α overexpression in oral squamous cell carcinoma: a meta-analysis , 2017, World Journal of Surgical Oncology.
[46] Benjamin D. Greenbaum,et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.
[47] R. Weinberg,et al. Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.
[48] E. Grande,et al. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. , 2017, Critical reviews in oncology/hematology.
[49] Matthew D Disney,et al. Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. , 2017, Journal of the American Chemical Society.
[50] N. McGranahan,et al. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.
[51] M. Rudin,et al. Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells , 2017, Current Biology.
[52] T. Tan,et al. Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity , 2017, Oncoimmunology.
[53] M. Konopleva,et al. Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy , 2017, Clinical Cancer Research.
[54] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[55] T. Tan,et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200 , 2017, Oncoimmunology.
[56] O. Cuvillier. The therapeutic potential of HIF-2 antagonism in renal cell carcinoma , 2017, Translational andrology and urology.
[57] Amanda B. Keener. Shapeshifters in cancer: How some tumor cells change phenotype to evade therapy , 2016, Nature Medicine.
[58] Hyejin Cho,et al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models , 2016, Nature.
[59] K. Gardner,et al. Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.
[60] A. Moustakas,et al. Transforming growth factor β as regulator of cancer stemness and metastasis , 2016, British Journal of Cancer.
[61] S. Påhlman,et al. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.
[62] M. Ferrer,et al. Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer , 2016, Clinical Cancer Research.
[63] C. Sarkar,et al. HIF-2α mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis. , 2016, The international journal of biochemistry & cell biology.
[64] E. Rankin,et al. Hypoxic control of metastasis , 2016, Science.
[65] A. Carnero,et al. The hypoxic microenvironment: A determinant of cancer stem cell evolution , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.
[66] Charles H. Yoon,et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.
[67] C. Pan,et al. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling , 2016, Oncotarget.
[68] Chuanzhao Zhang,et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA , 2016, Proceedings of the National Academy of Sciences.
[69] G. Salzano,et al. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors , 2016, Oncotarget.
[70] E. Ben-Jacob,et al. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome , 2016, Proceedings of the National Academy of Sciences.
[71] Qi Zhang,et al. Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. , 2016, Cancer research.
[72] S. Dedhar,et al. Targeting hypoxic response for cancer therapy , 2016, Oncotarget.
[73] Yong-Chen Lu,et al. Cancer immunotherapy targeting neoantigens. , 2016, Seminars in immunology.
[74] S. Terry,et al. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. , 2015, American journal of physiology. Cell physiology.
[75] G. Semenza,et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells , 2015, Proceedings of the National Academy of Sciences.
[76] G. Salzano,et al. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells , 2015, Oncotarget.
[77] P. Glazer,et al. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. , 2015, DNA repair.
[78] Ash A. Alizadeh,et al. Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .
[79] C. Elly,et al. E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity. , 2015, Immunity.
[80] Meiyan Wu,et al. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer , 2015, PloS one.
[81] Yang Liu,et al. Hypoxia-inducible factors in cancer stem cells and inflammation. , 2015, Trends in pharmacological sciences.
[82] Y. Murayama,et al. Emerging roles of hypoxia‐inducible factors and reactive oxygen species in cancer and pluripotent stem cells , 2015, The Kaohsiung journal of medical sciences.
[83] Sha Cao,et al. Cancer may be a pathway to cell survival under persistent hypoxia and elevated ROS: A model for solid‐cancer initiation and early development , 2015, International journal of cancer.
[84] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[85] Akio Ohta,et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation , 2015, Science Translational Medicine.
[86] P. Validire,et al. CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.
[87] Lu Ding,et al. miR-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell. , 2015, International journal of clinical and experimental medicine.
[88] M. Chilosi,et al. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells , 2015, British Journal of Cancer.
[89] H. Beltran,et al. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities , 2015, OncoTarget.
[90] G. Calin,et al. Hypoxia Mediated Downregulation of miRNA Biogenesis Promotes Tumor Progression , 2014, Nature Communications.
[91] Lixia Diao,et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.
[92] Paul C. Boutros,et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER , 2014, Nature Communications.
[93] R. Weinberg,et al. Tackling the cancer stem cells — what challenges do they pose? , 2014, Nature Reviews Drug Discovery.
[94] T. Tan,et al. Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression , 2014, Oncogene.
[95] H. Yao,et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. , 2014, Cancer cell.
[96] P. Dessen,et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.
[97] K. Tsang,et al. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. , 2014, Cancer research.
[98] M. Pawlus,et al. STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells , 2014, Oncogene.
[99] M. Ferrari,et al. XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.
[100] M. Bernaudin,et al. Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. , 2014, Investigative ophthalmology & visual science.
[101] Kou-Juey Wu,et al. Epigenetic regulation of hypoxia‐responsive gene expression: Focusing on chromatin and DNA modifications , 2014, International journal of cancer.
[102] Gwendoline Gros,et al. Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF-β1 , 2013, The Journal of Immunology.
[103] Paola Chiarugi,et al. Microenvironment and tumor cell plasticity: an easy way out. , 2013, Cancer letters.
[104] N. Inoue,et al. Hypoxia-Induced Reactive Oxygen Species Cause Chromosomal Abnormalities in Endothelial Cells in the Tumor Microenvironment , 2013, PloS one.
[105] R. Bristow,et al. Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.
[106] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[107] P. Xie,et al. M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway , 2013, Laboratory Investigation.
[108] A. G. de Herreros,et al. Epithelial–Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor , 2013, The Journal of Immunology.
[109] T. Tan,et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. , 2013, Cancer research.
[110] A. Bovier,et al. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.
[111] A. Tsimberidou,et al. Anti-vascular endothelial growth factor therapy in the era of personalized medicine , 2013, Cancer Chemotherapy and Pharmacology.
[112] Kou-Juey Wu,et al. Hypoxia-regulated target genes implicated in tumor metastasis , 2012, Journal of Biomedical Science.
[113] T. Hagemann,et al. The tumor microenvironment at a glance , 2012, Journal of Cell Science.
[114] J. Landsberg,et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.
[115] R. Weinberg,et al. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.
[116] E. Clambey,et al. Hypoxia-inducible factor-1 alpha–dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa , 2012, Proceedings of the National Academy of Sciences.
[117] P. Romero,et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. , 2012, Cancer research.
[118] G. Semenza,et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.
[119] G. Semenza,et al. Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.
[120] D. Tang,et al. Understanding cancer stem cell heterogeneity and plasticity , 2012, Cell Research.
[121] I. Melero,et al. Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer , 2011, Clinical Cancer Research.
[122] N. Marchionni,et al. NOTCH SIGNALLING MODULATES HYPOXIA-INDUCED NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CANCER CELLS , 2012 .
[123] Lin Zhang,et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.
[124] Y. Matsumoto,et al. Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia, and reoxygenation. , 2011, Journal of radiation research.
[125] Xiuping Liu,et al. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. , 2011, Cancer research.
[126] W. Wilson,et al. Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.
[127] P. Puigserver,et al. A Hypoxia-Induced Positive Feedback Loop Promotes Hypoxia-Inducible Factor 1α Stability through miR-210 Suppression of Glycerol-3-Phosphate Dehydrogenase 1-Like , 2011, Molecular and Cellular Biology.
[128] W. Bodmer,et al. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells , 2011, Proceedings of the National Academy of Sciences.
[129] M. Post,et al. Mouse Snail Is a Target Gene for HIF , 2011, Molecular Cancer Research.
[130] C. Marsh,et al. Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes. , 2011, Blood.
[131] T. Padhya,et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.
[132] W. Wong,et al. Hypoxia-inducible factors and the response to hypoxic stress. , 2010, Molecular cell.
[133] R. Cardiff,et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. , 2010, Cancer cell.
[134] Nadira Trncic,et al. Hypoxia/Reoxygenation-Induced Mutations in Mammalian Cells Detected by the Flow Cytometry Mutation Assay and Characterized by Mutant Spectrum , 2010, Radiation research.
[135] G. Semenza. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.
[136] A. Harris,et al. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. , 2010, Cancer research.
[137] M. Wei,et al. New strategies for cancer gene therapy: Progress and opportunities , 2010, Clinical and experimental pharmacology & physiology.
[138] K. Eckardt,et al. The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia , 2009, The Journal of Biological Chemistry.
[139] A. Arai,et al. Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. , 2009, The American journal of pathology.
[140] M. Simon,et al. Hypoxia-inducible factors in stem cells and cancer , 2009, Journal of cellular and molecular medicine.
[141] Huafeng Zhang,et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.
[142] J. Arbeit,et al. Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. , 2009, Cancer research.
[143] Jun O. Liu,et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.
[144] A. Sica,et al. Divergent effects of hypoxia on dendritic cell functions. , 2008, Blood.
[145] Tae-You Kim,et al. STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination , 2008, Experimental & Molecular Medicine.
[146] R. Roberts,et al. Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. , 2008, Stem cells and development.
[147] U. Lendahl,et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.
[148] Richard P. Hill,et al. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.
[149] Kou-Juey Wu,et al. Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.
[150] D. Kirkpatrick,et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α , 2008, Molecular Cancer Therapeutics.
[151] Brian Keith,et al. Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.
[152] V. Lazar,et al. αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis , 2007, The Journal of experimental medicine.
[153] M. Charbonneau,et al. Transforming Growth Factor β1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression* , 2006, Journal of Biological Chemistry.
[154] Quynh-Thu Le,et al. Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.
[155] Brian Keith,et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. , 2006, Genes & development.
[156] J. Massagué,et al. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.
[157] G. Semenza,et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.
[158] Jung Weon Lee,et al. The FASEB Journal express article 10.1096/fj.04-3099fje. Published online May 26, 2005. ©2005 FASEB , 2022 .
[159] W. Linehan,et al. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. , 2005, Cancer research.
[160] P. Glazer,et al. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. , 2005, Mutation research.
[161] K. Blackwell,et al. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? , 2004, The oncologist.
[162] Paul Lizardi,et al. Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells , 2004, Molecular and Cellular Biology.
[163] J. Zavadil,et al. Integration of TGF‐β/Smad and Jagged1/Notch signalling in epithelial‐to‐mesenchymal transition , 2004 .
[164] G. Paine-Murrieta,et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.
[165] Y. Pommier,et al. Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.
[166] P. Glazer,et al. Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells , 2003, Molecular and Cellular Biology.
[167] D. Scudiero,et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.
[168] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[169] P. Glazer,et al. Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.
[170] David E. Housman,et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.
[171] G. Semenza,et al. Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.
[172] V. Gopalan,et al. The clinical and biological roles of transforming growth factor beta in colon cancer stem cells: A systematic review. , 2018, European journal of cell biology.
[173] Jean Paul Thiery,et al. EMT: 2016 , 2016, Cell.
[174] M. Simon,et al. HIF-2 (cid:1) regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth , 2006 .
[175] M. Dewhirst,et al. Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. , 2001, Cancer research.